Who Paid My Doc
Trace Dotson
Emergency Medical Services Warren, MI Doctor of Osteopathy
NPI 1518987072 CMS profile 1203396
118000 E Twelve Mile Road, Er Department, Warren, MI 48093
General payments
$1,441
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, Trace Dotson of Warren, MI is reported in the CMS Open Payments database as having received $1,441 across 19 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 92nd percentile of Emergency Medical Services profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $24 | 1 | |
| 2022 | General | $355 | 3 | |
| 2021 | General | $347 | 5 | |
| 2020 | General | $117 | 3 | |
| 2019 | General | $598 | 7 |
Beside peers
- Trace Dotson
- Emergency Medical Services median
- Middle half of Emergency Medical Services
- National median
In program year 2025, general payments to Trace Dotson were reported at $0. Among 443 Emergency Medical Services profiles paid that year, the median was $72 and the middle half received between $25 and $169.
Show as a table
| Year | Trace Dotson | Emergency Medical Services median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $598 | $62 | $20–$162 | $163 |
| 2020 | $117 | $37 | $17–$119 | $114 |
| 2021 | $347 | $58 | $20–$133 | $132 |
| 2022 | $355 | $61 | $21–$156 | $149 |
| 2023 | $24 | $58 | $21–$173 | $160 |
| 2024 | $0 | $62 | $24–$161 | $164 |
| 2025 | $0 | $72 | $25–$169 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 16 drugsPart D claims
733
Drug cost
$4,648
Branded share of claims
14.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Albuterol Sulfate Hfa Albuterol Sulfate | Brand | 29 | $780 | |
| Cefdinir | Generic | 38 | $636 | |
| Methylprednisolone | Generic | 89 | $572 | |
| Azithromycin | Generic | 102 | $446 | |
| Ibuprofen | Generic | 89 | $287 | |
| Ciprofloxacin Hcl | Generic | 34 | $285 | |
| Cephalexin | Generic | 47 | $271 | |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | Brand | 25 | $258 | |
| Naproxen | Generic | 58 | $222 | |
| Doxycycline Hyclate | Generic | 32 | $221 |
The 10 drugs with the highest cost, of 16 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 40,243 Part D prescribers listed as Emergency Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 115 billing codesPaid by Medicare
$56,494
Medicare patients
240
Services billed
3,041
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 58% | |
| Ischemic heart disease | 39% | |
| Diabetes | 32% | |
| Chronic kidney disease | 30% | |
| Depression | 23% | |
| Osteoporosis | 19% | |
| Heart failure | 18% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, orphenadrine citrate, up to 60 mg J2360 | Office | 16 | 17 | $109 |
| Infusion, normal saline solution , 1000 cc J7030 | Office | 36 | 40 | $83 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 82 | 686 | $57 |
| Injection, ketorolac tromethamine, per 15 mg J1885 | Office | 46 | 97 | $46 |
| Injection, ceftriaxone sodium, per 250 mg J0696 | Office | 34 | 109 | $39 |
| Injection, ondansetron hydrochloride, per 1 mg J2405 | Office | 12 | 42 | $3 |
| Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme J7620 | Office | 15 | 16 | $2 |
| Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg J7613 | Office | 12 | 31 | $1 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
19 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Emergency Medical Services in Michigan
Charles Zeller
Emergency Medical Services · Kalamazoo, MI
Melissa Taylor
Emergency Medical Services · Grand Rapids, MI
Joshua White
Emergency Medical Services · Lansing, MI
Robert Dunne
Emergency Medical Services · Detroit, MI
Brian Gelb
Emergency Medical Services · Alpena, MI
Timothy Childers
Emergency Medical Services · Reed City, MI
Related records
Emergency Medical Services in Michigan
Practitioners in the same specialty and state, ranked by reported value.
All Emergency Medical Services
Everyone recorded under this specialty, nationwide.
Doctors in Michigan
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.